5-MeO-NMT
5-MeO-NMT, also known as 5-methoxy-N-methyltryptamine, is an tryptamine alkaloid, being the 5-methoxy analogue of N-methyltryptamine. It was first isolated from Phalaris arundinacea and also occurs in other species such as Virola species and Bufo alvarius skin. The compound has been synthesized by Alexander Shulgin and reported in his book TiHKAL.
Use and effects
Alexander Shulgin included 5-MeO-NMT as an entry in his book TiHKAL. However, he does not appear to have tested it and states that the dose and duration of the compound are unknown. In any case, Shulgin stated that it would be expected to be rapidly metabolized by monoamine oxidase and that it would likely only be active parenterally.Pharmacology
Pharmacodynamics
5-MeO-NMT is a potent agonist of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors. It is a full agonist or near-full agonist of all of these receptors except for the serotonin 5-HT1A receptor, where it is a partial agonist. It additionally displays a high affinity for multiple other serotonin receptors. The drug is also a very weak serotonin releasing agent and has sub micromolar affinity for dopamine D4 receptor.There is conflicting data on its effects in mammals. In a study in 1964, Taborsky and McIsaac found 5-methoxy-NMT to have a 'moderately disruptive effect on conditioned behavior' in rats. Another study found it does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and in some cases even reduced total HTRs. On the other hand, it does induce serotonin 5-HT1A receptor-mediated hypothermia and hypolocomotion. Earlier reports had stated that 5-MeO-NMT and its N-demethylated analogue 5-methoxytryptamine were inactive, but this proved not to be the case.